Deals and IPOs

Actavis to buy Allergan for $66 billion

CNBC with Reuters
Actavis to buy Allergan in $66 billion deal
Actavis to buy Allergan in $66 billion deal
Actavis CEO: Allergan best run pharma company
Actavis CEO: Allergan best run pharma company
Why Allergan never engaged Valeant
Why Allergan never engaged Valeant

Actavis announced on Monday that it will acquire Allergan for $66 billion, or $219 per share in cash and Actavis shares.

The deal beats the unsolicited bid last spring of above $50 billion from Valeant, which teamed with Bill Ackman's hedge fund Pershing Square Capital Management.

Valeant Chairman and CEO J. Michael Pearson said in a statement that his firm "cannot justify to its own shareholders paying a price of $219 or more per share for Allergan."

Read MoreHalliburton in blockbuster oilfield services deal

"This combination will greatly enhance our U.S. and international commercial opportunities," said Paul Bisaro, executive chairman of Actavis.

The combined company of Activis and Allergan will have an expected $23 billion in revenue and will be led by Brent Saunders, CEO and president of Actavis. Bisaro will remain executive chairman, the company said.

"Today's transaction provides Allergan stockholders with substantial and immediate value, as well as the opportunity to participate in the significant upside potential of the combined company," David E. I. Pyott, chairman and CEO of Allergan, said in a statement.

Allergan has spent six months maneuvering against a takeover by Ackman and Valeant, including in a legal battle. Pyott had said shareholders would be hurt because Valeant's cost-cutting, particularly in research and development, would stop its growth, and he questioned Valeant's accounting.

In a conference call following the announcement, Pyott said the decision to accept Actavis' offer was related to similarities between the two companies' commitment to research and development, to which the combined company will dedicate about $1.7 billion annually.

Read MoreAllergan deal a win for more than Ackman

A representative from Pershing Square did not have an immediate comment.

Allergan shares rose as high as 6.6 percent to $211, earning Ackman a payout of more than $2.4 billion on his nearly 10 percent stake in the company.

Reuters contributed to this report.